



# FINANCIAL STATEMENTS

## CONTENTS

### GROUP FINANCIAL STATEMENTS

- 162 Independent auditors' report
- 171 Consolidated statement of financial position
- 172 Consolidated income statement
- 173 Consolidated statement of other comprehensive income
- 174 Consolidated statement of changes in equity
- 176 Consolidated statement of cash flows
- 177 Notes to the consolidated financial statements
- 243 Annexure – Investments in subsidiaries, associates and joint ventures

### COMPANY FINANCIAL STATEMENTS

- 248 Independent auditors' report
- 253 Company statement of financial position
- 254 Company statement of changes in equity
- 255 Company statement of cash flows
- 256 Notes to the Company financial statements

## GENERAL INFORMATION

These financial statements are consolidated financial statements for Mediclinic International plc (the “**Company**”) and its subsidiaries, associates and joint ventures (the “**Group**”). A list of subsidiaries, associates and joint ventures is included from pages 243 to 247.

Mediclinic International plc (the “**Company**”) is a public limited company, listed on the London Stock Exchange and is incorporated and domiciled in England and Wales. The Company has secondary listings on the Johannesburg Stock Exchange (“**JSE**”) and the Namibian Stock Exchange (“**NSX**”). A wholly-owned subsidiary, Hirslanden AG issued bonds listed on the SIX.

Registered Address:  
6th Floor  
65 Gresham Street  
London  
EC2V 7NQ  
United Kingdom

The core purpose of the Group is to enhance the quality of life of patients by providing value-based healthcare services.

The financial statements were authorised for issue by the Directors on 23 May 2018. No authority was given to anyone to amend the financial statements after the date of issue.

All press releases, financial reports and other information are available on our website: [www.mediclinic.com](http://www.mediclinic.com).